Sandra Levy
ARTICLES BY THIS AUTHOR
- 6/8/2022
Walmart names finalists to pitch at 2022 Open Call event
Suppliers with products made, grown or assembled in the United States will meet one-on-one with Walmart merchants during the June 28 to 29 event. - 6/7/2022
Amneal debuts 2 generics
The company is offering Lyvispah, a baclofen oral granules specialty product, and bexarotene gel, 1%. - 6/7/2022
NACDS: Momentum builds for bipartisan legislation to protect Americans’ access to pharmacist care
The Equitable Community Access to Pharmacist Services Act (HR 7213) would help ensure the continuity of accessible pharmacy-based care during public health emergencies and every day, NACDS states. - 6/7/2022
Sam’s Club gets Georgia-Pacific brands delivered to stores 24/7
Sam’s Club is poised to receive Georgia-Pacific products with reliability, speed and consistency, thanks to a partnership with Gatik. - 6/6/2022
Meijer reflects on evolution of its supercenters
Meijer is reflecting on how far it has come in serving customers some 60 years since the opening of a store in Grand Rapids, Mich., dubbed Thrifty Acres. - 6/6/2022
Fresenius Kabi intros generic Alimta
The medication is used for adult patients with non-squamous non-small cell lung cancer and malignant pleural mesothelioma. - 6/6/2022
Target updates 2022 plan focused on inventory optimization
Target is planning several actions in the second quarter, including additional markdowns, removing excess inventory and canceling orders. - 6/5/2022
FDA launches dietary supplement education initiative
Supplement Your Knowledge resources is intended to provide reliable information about the potential benefits and risks associated with dietary supplements, such as vitamins, minerals and herbs. - 6/5/2022
Amazon’s Dave Clark departs company
Dave Clark is leaving Amazon as CEO of worldwide consumer services on July 1. - 6/5/2022
Sandoz launches global Act4Biosimilars initiative
Act4Biosimilars aims to increase patient access to advanced medicines by facilitating greater approvability, accessibility, acceptability and affordability (the four A’s) of biosimilars.
